Cochrane · systematic review · CD001416
Zonisamide add‐on therapy for focal epilepsy
Brigo, F, Lattanzi, S, Igwe, SC, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 6 · 85.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsZonisamide compared to placebo for focal epilepsy
Population: patients with focal epilepsy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
50% responder rate (whole treatment period; any dose) Zonisamide vs placebo | RR 1.86 [1.6, 2.17] | 7 studies · 1429 participants | Moderate Downgraded: risk of bias |
Withdrawal rates (whole treatment period; any dose) Zonisamide vs placebo | RR 1.44 [1.08, 1.93] | 6 studies · 1156 participants | Moderate Downgraded: risk of bias |
Adverse effects: ataxia (whole treatment period; any dose) Zonisamide vs placebo | RR 3.85 | 4 studies · 734 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: dizziness (whole treatment period; any dose) Zonisamide vs placebo | RR 1.4 | 7 studies · 1429 participants | Moderate Downgraded: risk of bias |
Adverse effects: fatigue (whole treatment period; any dose) Zonisamide vs placebo | RR 1.41 | 6 studies · 1045 participants | Moderate Downgraded: risk of bias |
Adverse effects: nausea (whole treatment period; any dose) Zonisamide vs placebo | RR 1.1 | 5 studies · 805 participants | Moderate Downgraded: risk of bias |
Adverse effects: somnolence (whole treatment period; any dose) Zonisamide vs placebo | RR 1.52 | 8 studies · 1636 participants | Moderate Downgraded: risk of bias |